I5T-MC-AACM - ClinicalTrials.gov - NCT05026866
I5T-MC-AACM - ClinicalTrials.gov - NCT05026866
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a reliable study partner with whom they have regular contact and who can be contacted during the study
Participants must NOT
Participants must not have been diagnosed with a condition that causes memory or thinking problems such as dementia or early dementia, or a significant disease of the brain
Participants must not have a serious medical condition, such as a neurologic or psychiatric illness, or a history of a serious medical condition, including certain types of cancers
Participants must not have a history of severe drug allergies or hypersensitivity reactions
Participants must not have any allergies to Donanemab or its components
Participants must not have certain health conditions that prevent them from getting an MRI
Participants must not have certain abnormal lab or MRI values at screening
Participants must not have taken certain medicines or had certain treatments
Participant must not be pregnant or can become pregnant during the study (for example, have not had menopause or ovary removal)
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease, At Risk For Alzheimer's
What the trial is testing?
Donanemab, LY3002813
Could I receive a Placebo?
yes
Enrollment Goal
3300
Trial Dates
August 2021 - November 2027
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a reliable study partner with whom they have regular contact and who can be contacted during the study
Participants must NOT
Participants must not have been diagnosed with a condition that causes memory or thinking problems such as dementia or early dementia, or a significant disease of the brain
Participants must not have a serious medical condition, such as a neurologic or psychiatric illness, or a history of a serious medical condition, including certain types of cancers
Participants must not have a history of severe drug allergies or hypersensitivity reactions
Participants must not have any allergies to Donanemab or its components
Participants must not have certain health conditions that prevent them from getting an MRI
Participants must not have certain abnormal lab or MRI values at screening
Participants must not have taken certain medicines or had certain treatments
Participant must not be pregnant or can become pregnant during the study (for example, have not had menopause or ovary removal)
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease, At Risk For Alzheimer's
What the trial is testing?
Donanemab, LY3002813
Could I receive a Placebo?
yes
Enrollment Goal
3300
Trial Dates
August 2021 - November 2027
Trial Phase
3
Trial Locations
Hide locations not currently recruiting
By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy